Tackling Coronavirus
Through Science and Collaboration
CARE
(Corona Accelerated R&D in Europe) is the largest European research initiative addressing the challenges of COVID-19. With a coalition of Europe’s best scientific minds from 38 globally-renowned research institutions and pharmaceutical companies, together with partners from the USA and China it provides a multi-disciplinary team with proven expertise and capabilities in anti-viral drug development.
WATCH THE PRESENTATION
NEWS
THE CARE CONSORTIUM ADDRESSES THREE MAIN GOALS
1
EMERGENCY RESPONSE
The development of therapeutics to provide an emergency response towards the current COVID-19 pandemic.
Drug positioning / repurposing
Screening and profiling compound libraries to progress molecules to advanced stages of clinical testing within 18 months.
2
LONG TERM STRATEGY
The development of therapeutics to address the current and/or future coronavirus outbreaks.
Small molecule drug discovery
Target-based and in silico screening and profiling of candidate compounds against SARS-CoV-2 for clinical testing in 36 months.
Virus-neutralising antibody discovery
Fully human phage and yeast display, immunisation of humanised models, patient B cells and in silico design for clinical testing within 36 months.
3
INVESTIGATING COVID-19
Increasing the understanding of the physiopathology of COVID-19.
Immune marker discovery
Discovery of immune markers contributing to host-immune responses to COVID-19 infection and their correlations with clinical and virological outcomes.
KEY FIGURES
Ambition to accelerate effective therapies to COVID-19 patients in Europe and around the world, and generate a truly transformative treatment regimen.
The largest European research initiative addressing the challenges of COVID-19.
Coalition of Europe’s best scientific minds from 38 globally-renowned research institutions and pharmaceutical companies, together with partners from the USA and China.
A multi-disciplinary team with proven scientific and technical expertise and capabilities in anti-viral drug development.
75.8 million Euro investment over 5 years with a grant from the Innovative Medicines Initiative and contributions from EFPIA partners, IMI Associated Partners and other organisations.
Combines a focus on rapid emergency response with focus on long-term preparedness for future outbreaks.
CARE IN NUMBERS
38
International Partners
11
Countries
36,5
M€ funding from IMI
39,3
M€ co-funding by partners
5
Years duration (2020-2025)